Estradiol Transdermal Patch Rx
Generic Name and Formulations:
Estradiol 0.05mg/day, 0.1mg/day; ext-rel transdermal film.
Indications for Estradiol Transdermal Patch:
Moderate-to-severe vasomotor symptoms of menopause. Moderate-to-severe symptoms of vulvar and vaginal atrophy due to menopause. Hypoestrogenism. Prevention of postmenopausal osteoporosis.
Initially one 0.05mg/day patch twice per week applied to trunk (avoid breasts, waistline). May be given continuously if patient does not have an intact uterus or cyclically (3 weeks on, 1 week off) in patients with intact uterus. Rotate application sites. Osteoporosis: supplement diet with calcium 1.5 g/day and Vitamin D 400–800IU/day.
Undiagnosed abnormal genital bleeding. Breast or other estrogen-dependent neoplasms. Thromboembolic disorders (eg, DVT, PE, stroke, MI). Protein C, protein S, or antithrombin deficiency, or other thrombophilias. Hepatic impairment or disease. Pregnancy.
Endometrial cancer. Breast cancer. Cardiovascular disorders. Probable dementia.
Increased risk of endometrial carcinoma or hyperplasia in women with intact uterus (adding progestin is essential). Not for prevention of cardiovascular disease or dementia. Increased risk of cardiovascular events (eg, MI, stroke, VTE); discontinue if occurs. Manage risk factors for cardiovascular disease and venous thromboembolism appropriately. Discontinue at least 4–6 weeks before surgery type associated with increased risk of thromboembolism or during prolonged immobilization. Increased risk of breast or ovarian cancer. Risk of probable dementia in women >65yrs of age. Gallbladder disease. Severe hypercalcemia in breast cancer or bone metastases. Visual abnormalities. History of hypertriglyceridemia. Discontinue if cholestatic jaundice, pancreatitis, hypercalcemia, or retinal vascular lesions occur. Monitor thyroid function. Conditions aggravated by fluid retention. Hypoparathyroidism. Endometriosis. Hereditary angioedema. Asthma. Diabetes. Epilepsy. Migraine. Porphyria. SLE. Hepatic hemangiomas. Do initial complete physical and repeat annually (include Pap smear, mammogram, and BP). Reevaluate periodically. Nursing mothers: not recommended.
Concomitant thyroid replacement; may need to increase thyroid dose. May interfere with lab tests (eg, thyroid, PT, coagulation factors, glucose tolerance, HDL/LDL, triglycerides, hormone concentrations, other binding or plasma proteins).
Local redness and irritation; thromboembolism, neoplasms; rare: rash, allergic reactions, angioedema (permanently discontinue if occurs).
Formerly known under the brand name Estraderm.
Hepatic (CYP1A2, CYP3A4).
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Mood Stabilizers Associated With Increased Risk for Stroke in Bipolar Disorder
- Patients With Schizophrenia May Benefit From Occupational Therapy
- FDA Committees Vote on Opioid System Modulator for MDD Treatment
- Minocycline vs Routine Care for Clinical Symptom Improvement in Schizophrenia
- Methylphenidate for ADHD Treatment May Be Associated With Low BMI
- Cardioprotective Treatment May Reduce Adverse Effects in Schizophrenia
- Opioid Use Often Persists in Workers' Compensation Claimants
- Parental Mental Disorders Linked to Work Disabilities in Offspring
- Insomnia in Borderline Personality Disorder May Increase Suicide Risk
- Mortality Rates in Parkinson Disease Psychosis With Pimavanserin, Quetiapine